JP2016509222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509222A5 JP2016509222A5 JP2015556042A JP2015556042A JP2016509222A5 JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- subject
- biomarkers
- level
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 8
- SATGKQGFUDXGAX-MYWFJNCASA-N 7alpha-hydroxy-3-oxo-4-cholestenoic acid Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)C(O)=O)C)[C@@]1(C)CC2 SATGKQGFUDXGAX-MYWFJNCASA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- YAADMLWHGMUGQL-VOTSOKGWSA-N N-cinnamoylglycine Chemical compound OC(=O)CNC(=O)\C=C\C1=CC=CC=C1 YAADMLWHGMUGQL-VOTSOKGWSA-N 0.000 claims 6
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 6
- 229960003964 deoxycholic acid Drugs 0.000 claims 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 6
- 229960002743 glutamine Drugs 0.000 claims 6
- 229960002449 glycine Drugs 0.000 claims 6
- 229950009829 prasterone sulfate Drugs 0.000 claims 6
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 6
- 229960004441 tyrosine Drugs 0.000 claims 6
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 claims 5
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 5
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 5
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 5
- 229940116269 uric acid Drugs 0.000 claims 5
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 claims 4
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 claims 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims 4
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 4
- 206010056474 Erythrosis Diseases 0.000 claims 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- JXRLHZCEMXTCBN-DIBGMJQNSA-N [Hyp(3)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 JXRLHZCEMXTCBN-DIBGMJQNSA-N 0.000 claims 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
- ONJSZLXSECQROL-UHFFFAOYSA-N alpha-hydroxyhippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1O ONJSZLXSECQROL-UHFFFAOYSA-N 0.000 claims 4
- 150000003278 haem Chemical class 0.000 claims 4
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 4
- 229960000310 isoleucine Drugs 0.000 claims 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 4
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 4
- MZPWKJZDOCIALD-UHFFFAOYSA-N pyrocatechol sulfate Chemical compound OC1=CC=CC=C1OS(O)(=O)=O MZPWKJZDOCIALD-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 3
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims 2
- IPOLTUVFXFHAHI-WHIOSMTNSA-N (R)-oleoylcarnitine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IPOLTUVFXFHAHI-WHIOSMTNSA-N 0.000 claims 2
- OTSBKHHWSQYEHK-UHFFFAOYSA-N 1,3-dimethyluric acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(=O)N2 OTSBKHHWSQYEHK-UHFFFAOYSA-N 0.000 claims 2
- NOFNCLGCUJJPKU-UHFFFAOYSA-N 1,7-dimethyluric acid Chemical compound N1C(=O)N(C)C(=O)C2=C1NC(=O)N2C NOFNCLGCUJJPKU-UHFFFAOYSA-N 0.000 claims 2
- FGWUDHZVEBFGKS-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl azetidine-1,2-dicarboxylate Chemical compound COC(=O)C1CCN1C(=O)OC(C)(C)C FGWUDHZVEBFGKS-UHFFFAOYSA-N 0.000 claims 2
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 claims 2
- YNOWULSFLVIUDH-UHFFFAOYSA-O 3-dehydrocarnitinium Chemical compound C[N+](C)(C)CC(=O)CC(O)=O YNOWULSFLVIUDH-UHFFFAOYSA-O 0.000 claims 2
- HHDDCCUIIUWNGJ-UHFFFAOYSA-N 3-hydroxypyruvic acid Chemical compound OCC(=O)C(O)=O HHDDCCUIIUWNGJ-UHFFFAOYSA-N 0.000 claims 2
- KWNBDPJHEKVDAW-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(4-methylphenyl)-4-oxobutanoic acid Chemical compound C1=CC(C)=CC=C1C(C(O)=O)CC(=O)C1=CC=C(Cl)C=C1 KWNBDPJHEKVDAW-UHFFFAOYSA-N 0.000 claims 2
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 2
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 claims 2
- UFAHZIUFPNSHSL-UHFFFAOYSA-N O-propanoylcarnitine Chemical compound CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-UHFFFAOYSA-N 0.000 claims 2
- 229960001009 acetylcarnitine Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- ZGRRONMCJIREIE-UHFFFAOYSA-N benzyl n-[1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]-n-methylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)N(C)C(C=1C=CC(Cl)=CC=1)CCN1CCCC1 ZGRRONMCJIREIE-UHFFFAOYSA-N 0.000 claims 2
- 150000002009 diols Chemical class 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 208000018914 glucose metabolism disease Diseases 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 2
- 229940075559 piperine Drugs 0.000 claims 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 2
- 235000019100 piperine Nutrition 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 238000007619 statistical method Methods 0.000 claims 2
- BYXCFUMGEBZDDI-UHFFFAOYSA-N trimethyluric acid Natural products CN1C(=O)N(C)C(=O)C2=C1NC(=O)N2C BYXCFUMGEBZDDI-UHFFFAOYSA-N 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 238000007681 bariatric surgery Methods 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 claims 1
- 235000006694 eating habits Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000007477 logistic regression Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361758924P | 2013-01-31 | 2013-01-31 | |
| US61/758,924 | 2013-01-31 | ||
| PCT/US2014/011759 WO2014120449A1 (en) | 2013-01-31 | 2014-01-16 | Biomarkers related to insulin resistance progression and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509222A JP2016509222A (ja) | 2016-03-24 |
| JP2016509222A5 true JP2016509222A5 (enExample) | 2017-02-09 |
| JP6404834B2 JP6404834B2 (ja) | 2018-10-17 |
Family
ID=51262841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556042A Active JP6404834B2 (ja) | 2013-01-31 | 2014-01-16 | インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9910047B2 (enExample) |
| EP (2) | EP2951313B1 (enExample) |
| JP (1) | JP6404834B2 (enExample) |
| ES (2) | ES2669620T3 (enExample) |
| WO (1) | WO2014120449A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014243259B2 (en) * | 2013-03-28 | 2019-04-18 | Société des Produits Nestlé S.A. | Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention |
| MX2016000293A (es) * | 2013-07-09 | 2016-06-21 | Stemina Biomarker Discovery Inc | Biomarcadores del trastrono del espectro autista. |
| WO2017200025A1 (ja) * | 2016-05-17 | 2017-11-23 | 国立大学法人大阪大学 | 糖尿病を判定するための血液試料の分析方法及びシステム |
| CA3026049C (en) | 2016-06-02 | 2024-04-09 | Metabolon, Inc. | Mass spectrometry method for detection and quantitation of metabolites |
| CN110088615B (zh) * | 2016-12-19 | 2023-08-22 | 梅塔博隆股份有限公司 | 用于肾功能代谢物的检测和定量的质谱法测定方法 |
| WO2018150077A1 (en) * | 2017-02-16 | 2018-08-23 | Afekta Technologies Oy | Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases |
| EP3602071B1 (en) * | 2017-03-31 | 2022-12-07 | Quest Diagnostics Investments LLC | Methods for quantitation of insulin and c-peptide |
| EP3401683A1 (en) * | 2017-05-10 | 2018-11-14 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Diagnosing metabolic disease by the use of a biomarker |
| EP3740200B1 (en) * | 2018-01-17 | 2024-12-11 | University Of Southampton | Methods to predict risk of and to stratify sarcopenia and nad deficiency |
| WO2020064690A1 (en) * | 2018-09-27 | 2020-04-02 | Société des Produits Nestlé S.A. | Markers of risk to develop insulin resistance during childhood and young adulthood |
| US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
| KR102231928B1 (ko) * | 2019-09-19 | 2021-03-26 | 고려대학교 산학협력단 | 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물 |
| CA3177108A1 (en) * | 2020-04-27 | 2021-11-04 | Wayne R. Matson | Detection and modification of gut microbial population |
| CN112149311B (zh) * | 2020-10-12 | 2021-10-26 | 北京中恒利华石油技术研究所 | 一种基于数量规约的非线性多元统计回归测井曲线预测方法 |
| CN112843036A (zh) * | 2021-01-29 | 2021-05-28 | 中国药科大学 | β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用 |
| CN116087487B (zh) * | 2021-11-08 | 2025-06-03 | 中国医学科学院阜外医院 | 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途 |
| CN114324662B (zh) * | 2021-12-30 | 2022-09-16 | 中南大学 | 用于诊断或预防糖尿病的血清生物标志物的应用 |
| WO2023194615A1 (en) * | 2022-04-07 | 2023-10-12 | Need4Health B.V. | Method for determining insulin dosage |
| JP7736971B2 (ja) * | 2022-10-18 | 2025-09-10 | 株式会社オルトメディコ | 糖尿病境界域者のスクリーニング方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1285092A4 (en) | 2000-04-14 | 2003-07-16 | Metabolon Inc | METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| CA2529759A1 (en) | 2003-06-20 | 2005-10-13 | University Of Florida | Biomarkers for differentiating between type 2 and type 2 diabetes |
| US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
| US8119358B2 (en) | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| EP2369346B1 (en) * | 2006-03-24 | 2014-08-27 | Metanomics GmbH | Method for diagnosing diabetes type II |
| EP2164977B1 (en) * | 2007-07-17 | 2013-10-30 | Metabolon, Inc. | Biomarkers for pre-diabetes and methods using the same |
| WO2010005982A2 (en) * | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| US20110113863A1 (en) * | 2008-07-15 | 2011-05-19 | Metanomics Health Gmbh | Means and methods diagnosing gastric bypass and conditions related thereto |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
| US8367418B2 (en) | 2009-10-23 | 2013-02-05 | Therasyn Sensors, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| WO2011059721A1 (en) * | 2009-10-29 | 2011-05-19 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
| US20140303228A1 (en) * | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
| US20150065366A1 (en) * | 2011-11-11 | 2015-03-05 | Metabolon, Inc. | Biomarkers for Bladder Cancer and Methods Using the Same |
| AU2012347557A1 (en) * | 2011-12-09 | 2014-07-03 | Metabolon, Inc. | Biomarkers for kidney cancer and methods using the same |
-
2014
- 2014-01-16 JP JP2015556042A patent/JP6404834B2/ja active Active
- 2014-01-16 US US14/763,962 patent/US9910047B2/en active Active
- 2014-01-16 EP EP14746017.4A patent/EP2951313B1/en active Active
- 2014-01-16 ES ES14746017.4T patent/ES2669620T3/es active Active
- 2014-01-16 WO PCT/US2014/011759 patent/WO2014120449A1/en not_active Ceased
- 2014-01-16 EP EP17209399.9A patent/EP3321686B1/en active Active
- 2014-01-16 ES ES17209399T patent/ES2987582T3/es active Active
-
2018
- 2018-01-16 US US15/872,373 patent/US20180203021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509222A5 (enExample) | ||
| Vaes et al. | Changes in physical activity and all-cause mortality in COPD | |
| Kim et al. | Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea | |
| ter Horst et al. | Methods for quantifying adipose tissue insulin resistance in overweight/obese humans | |
| Henderson et al. | How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children? | |
| Vandoni et al. | Six minute walk distance and reference values in healthy Italian children: A cross-sectional study | |
| ES2669620T3 (es) | Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan | |
| Durrer et al. | Differential impact of acute high-intensity exercise on circulating endothelial microparticles and insulin resistance between overweight/obese males and females | |
| Reijnierse et al. | The association between parameters of malnutrition and diagnostic measures of sarcopenia in geriatric outpatients | |
| Roumen et al. | Predictors of lifestyle intervention outcome and dropout: the SLIM study | |
| Fernández-Sanjurjo et al. | Circulating microRNA as emerging biomarkers of exercise | |
| JP2018502286A5 (enExample) | ||
| Macinnis et al. | Methods to estimate V˙ O2max upon acute hypoxia exposure | |
| Pietrobelli et al. | Adipose tissue and metabolic effects: new insight into measurements | |
| Warrington et al. | Modelling BMI trajectories in children for genetic association studies | |
| García-Hermoso et al. | Fatness mediates the influence of muscular fitness on metabolic syndrome in Colombian collegiate students | |
| Zagatto et al. | Relationship between anaerobic capacity estimated using a single effort and 30-s tethered running outcomes | |
| Aerenhouts et al. | Estimating body composition in adolescent sprint athletes: Comparison of different methods in a 3 years longitudinal design | |
| Van Manen et al. | Scalp hair cortisol and testosterone levels in patients with sarcoidosis | |
| Ning et al. | Serum creatinine-and cystatin C-based indices are associated with the risk of subsequent sarcopenia: evidence from the China health and retirement longitudinal study | |
| Scott et al. | The intensity of a resistance exercise session can be quantified by the work rate of exercise | |
| Jayasinghe et al. | Fitter women did not have attenuated hemodynamic responses to psychological stress compared with age-matched women with lower levels of fitness | |
| Espinosa-Flores et al. | A scoping review of the methods used in patients with liver cirrhosis to assess body composition and their nutritional findings | |
| Tee et al. | Effects of exercise modality combined with moderate hypoxia on blood glucose regulation in adults with overweight | |
| Robertson et al. | A glossary for social-to-biological research |